New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2014
11:24 EDTARIA, YPF, UNGOptions with increasing implied volatility: UVXY ARIA BOIL YPF UNG
News For ARIA;YPF;UNG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
13:23 EDTYPFYPF, Petronas negotiating JV with Mexico's Pemex, FT reports
YPF and Petronas are in talks to form a joint venture with Pemex, the Financial Times reports. A tie-up could commence with shallow water fields, the publication adds. Reference Link
07:43 EDTYPFYPF CEO seeks faster non-conventional development, WSJ reports
Subscribe for More Information
07:36 EDTARIAARIAD presents updated clinical data on AP26113
ARIAD Pharmaceuticals announced updated clinical results on its investigational tyrosine kinase inhibitor, AP26113, in patients with advanced non-small cell lung cancer from an ongoing Phase 1/2 trial. These study results show sustained anti-tumor activity of AP26113 in patients with anaplastic lymphoma kinase positive NSCLC, including patients with active brain metastases. The updated Phase 1/2 trial now contains more mature data of AP26113, including increasing depth and durability of response in ALK+ NSCLC patients, as well as additional safety data. The updated results were presented on Saturday, September 27 at the 2014 European Cancer Congress held in Madrid, Spain. A total of 137 patients have been enrolled in the ongoing Phase 1/2 trial in the United States and Europe. The objectives of the Phase 1 portion of the trial were to characterize the safety and tolerability of AP26113, pharmacokinetics, and preliminary anti-tumor activity and to determine the recommended dose for further study of AP26113 in subsequent clinical trials. The trial used an open-label, dose-escalating design. The Phase 2 portion of the trial consists of five expansion cohorts. The data presented at ESMO focus on the 79 patients with a history of ALK+ NSCLC tumors in the entire trial. Fifty-six of these patients currently remain on study treatment.
September 24, 2014
08:11 EDTYPFKyle Bass discusses stake in YPF
Hayman Capital's Kyle Bass said on CNBC he has a stake in YPF and that Elliott Management's stance on Argentina is "immoral." Shares of the Argentina-based oil and gas company are up 1% to $37.24 in pre-market trading.
September 18, 2014
17:57 EDTARIAARIAD CEO buys 25K shares of company stock
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use